The chart below shows how CLB performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CLB sees a +0.28% change in stock price 10 days leading up to the earnings, and a -0.73% change 10 days following the report. On the earnings day itself, the stock moves by -0.68%. This data can give you a slight idea of what to expect for the next quarter's release.
Positive
Revenue Increase Analysis: Revenue was up 3%, compared to Q2 of 2024 and more than 7%, compared to Q3 of 2023.
Operating Income Improvement: The company saw solid sequential improvement in operating income, operating and earnings per share.
Revenue Increase in Q3: In Reservoir Description revenue for the third quarter was up 3%, compared to Q2 reflecting the continued improvement in market demand for our global rock and fluid laboratory services.
Operating Margin Improvement: Operating margins for Reservoir Description were 17%, up very nicely from 14% in Q2.
EPS and Operating Margin Improvement: For the full company, EPS was $0.25 per share, compared to $0.22 in Q2 of 2024 and operating margins improved sequentially from 13% to 14%.
Negative
Operating Income Improvement: The company saw solid sequential improvement in operating income, operating and earnings per share. Revenue was up 3%, compared to Q2 of 2024 and more than 7%, compared to Q3 of 2023.
Laboratory Services Demand Challenges: Despite the ongoing geopolitical conflicts that continued to negatively impact demand for laboratory services that are specifically tied to the assay of crude oil and derived products.
Debt Reduction and Leverage Improvement: The company’s net debt was reduced by nearly $12 million or 9%. This reduction in our outstanding debt also decreased our leverage ratio to 1.47, down from 1.66 last quarter.
Operating Margin Improvement: Operating margins for Reservoir Description were 17%, up very nicely from 14% in Q2. However, the segment is still experiencing headwinds from ongoing international geopolitical conflicts in the Middle East and Russia, Ukraine.
Q4 2024 Revenue Projections: The company’s fourth quarter 2024 revenue is projected to range from $128.5 million to $135.5 million with operating income of $14.8 million to $17.7 million, yielding operating margins of 12%.
Core Laboratories Inc. (CLB) Q3 2024 Earnings Call Transcript
CLB.N
-4.33%